These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 8294901

  • 1. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB, Riederer P.
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [Abstract] [Full Text] [Related]

  • 2. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB, Ben-Shachar D, Riederer P.
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB, Ben-Shachar D, Riederer P.
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [Abstract] [Full Text] [Related]

  • 5. Oxidative stress indices in Parkinson's disease : biochemical determination.
    Youdim MB, Drigues N, Mandel S.
    Methods Mol Med; 2001; 62():137-53. PubMed ID: 21318773
    [Abstract] [Full Text] [Related]

  • 6. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH, Kupsch A.
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [Abstract] [Full Text] [Related]

  • 7. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T.
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [Abstract] [Full Text] [Related]

  • 8. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dopaminergic neurons.
    Chinta SJ, Andersen JK.
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [Abstract] [Full Text] [Related]

  • 18. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE.
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [Abstract] [Full Text] [Related]

  • 19. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MB.
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [Abstract] [Full Text] [Related]

  • 20. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
    Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT.
    J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.